Muhammad I. Rehman

CD8αβ T Cells Are Not Essential to the Pathogenesis of Arthritis or Colitis in HLA-B27 Transgenic Rats

Ekkehard May, Martha L. Dorris, Nimman Satumtira et al. · The Journal of Immunology · 2003 · 171 citations · Full text

Life Sciences, Immunology, Pathology +15

A randomized controlled trial comparing PF-06438179/GP1111 (an infliximab biosimilar) and infliximab reference product for treatment of moderate to severe active rheumatoid arthritis despite methotrexate therapy

Stanley Cohen, Rieke Alten, Hideto Kameda et al. · Arthritis Research & Therapy · 2018 · 59 citations · Full text

Medicine, Pharmacology, Pharmacotherapy +16

A randomized study comparing the pharmacokinetics of the potential biosimilar PF-06438179/GP1111 with Remicade® (infliximab) in healthy subjects (REFLECTIONS B537-01)

Ramesh Palaparthy, Chandrasekhar Udata, Steven Y. Hua et al. · Expert Review of Clinical Immunology · 2018 · 25 citations

Pharmacy, Clinical Pharmacokinetics, Pharmacology +10

Long-term Efficacy, Safety, and Immunogenicity of the Infliximab (IFX) Biosimilar, PF-06438179/GP1111, in Patients with Rheumatoid Arthritis After Switching from Reference IFX or Continuing Biosimilar Therapy: Week 54–78 Data From a Randomized, Double-Blind, Phase III Trial

Stanley Cohen, S. Radominski, Hideto Kameda et al. · BioDrugs · 2020 · 16 citations · Full text

Medicine, Clinical Sciences, Pharmacotherapy +15

A comparative study of PF‐06438179/GP1111 (an infliximab biosimilar) and reference infliximab in patients with moderate to severe active rheumatoid arthritis: A subgroup analysis

Hideto Kameda, Eishi Uechi, Tatsuya Atsumi et al. · International Journal of Rheumatic Diseases · 2020 · 11 citations · Full text

Medicine, Pharmacology, Pharmacotherapy +14